Medicine and society: The use of highly active retroviral therapy to reduce HIV incidence at the population level

CMAJ. Canadian Medical Association Journal

Volumn 179, Issue 1, 2008, Pages 13-14

  Anema, Aranka ^a   Wood, Evan ^a   Montaner, Julio S G ^a,b  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b BRITISH COLUMBIA CENTRE FOR EXCELLENCE IN HIV AIDS   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; MICROBICIDE; VACCINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; CIRCUMCISION; DISEASE TRANSMISSION; EDUCATION; HEALTH CARE POLICY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; MATERNAL PLASMA; MEDICAL RESEARCH; NOTE; PROPHYLAXIS; PUBLIC HEALTH; VIRUS TRANSMISSION; ARTICLE; CANADA; EPIDEMIC;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CANADA; DISEASE OUTBREAKS; HEALTH POLICY; HIV INFECTIONS; HUMANS;

EID: 47049108877     PISSN: 08203946     EISSN: 14882329     Source Type: Journal    
DOI: 10.1503/cmaj.071809     Document Type: Note

References (13)

1. Brocklehurst P, Volmink J. Antiretrovirals for reducing the risk of mother-to-child transmission of HIV infection. Cochrane Database Syst Rev 2002;(2)CD003510.
2. Cohen MS, Gay C, Kashuba AD, et al. Narrative review: antiretroviral therapy to prevent the sexual transmission of HIV-1. Ann Intern Med 2007;146:591-601.
3. Tovanabutra S, Robison V, Wongtrakul J, et al. Male viral load and heterosexual transmission of HIV-1 subtype E in northern Thailand. J Acquir Immune Defic Syndr 2002;3:275-83.
4. Castilla J, Del Romero J, Hernando V, et al. Effectiveness of highly active antiretroviral therapy in reducing heterosexual transmission of HIV. J Acquir Immune Defic Syndr 2005;40:96-101.
5. Montaner JSG, Hogg RS, Wood E, et al. The case for expanding access to highly active anti-retroviral therapy to curb the growth of the HIV epidemic. Lancet 2006;368:531-6.
6. Fang CT, Hsu HM, Twu SJ, et al. Decreased HIV transmission after a policy of providing free access to highly active antiretroviral therapy in Taiwan. J Infect Dis 2004;190:879-85.
7. Abbas UL, Anderson RM, Mellors JW. Potential impact of antiretroviral therapy on HIV-1 transmission and AIDS mortality in resource-limited settings. J Acquir Immune Defic Syndr 2006;41:632-41.
8. Martinez V, Caumes E, Chosidow O. Treatment to prevent recurrent genital herpes. Curr Opin Infect Dis 2008;21:42-8.
9. Katz MH, Schwarcz SK, Kellogg TA, et al. Impact of highly active antiretroviral treatment on HIV seroincidence among men who have sex with men: San Francisco. Am J Public Health 2002;92:388-94.
10. Crepaz N, Hart TA, Marks G. Highly active antiretroviral therapy and sexual risk behavior: a meta-analytic review. JAMA 2004;292:224-36.
11. Lima VD, Hogg RS, et al. Expanded access to highly active antiretroviral therapy: a potentially powerful strategy to curb the growth of the HIV epidemic. J Infect Dis. In press.
12. Yerly S, Jost S, Telenti A, et al. Infrequent transmission of HIV-1 drug-resistant variants. Antivir Ther 2004;9:375-84.
13. Vernazza P, Hirschel B, Bernasconi E, et al. Les personnes séropositives ne souffrant d'aucune autre MST et suivant un traitement antirétroviral efficace ne transmettent pas le VIH par voie sexuelle. Bulletin des médecins suisses 2008;89:165-9.